Nisa Investment Advisors LLC Has $64.76 Million Stock Position in Merck & Co., Inc. $MRK

Nisa Investment Advisors LLC grew its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 19.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 809,798 shares of the company’s stock after purchasing an additional 132,370 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Merck & Co., Inc. were worth $64,764,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Peoples Financial Services CORP. lifted its position in shares of Merck & Co., Inc. by 0.5% in the second quarter. Peoples Financial Services CORP. now owns 22,778 shares of the company’s stock worth $1,803,000 after buying an additional 122 shares during the last quarter. McLean Asset Management Corp increased its holdings in shares of Merck & Co., Inc. by 3.7% during the 2nd quarter. McLean Asset Management Corp now owns 3,543 shares of the company’s stock valued at $292,000 after acquiring an additional 125 shares during the last quarter. Cora Capital Advisors LLC raised its stake in shares of Merck & Co., Inc. by 2.4% in the 2nd quarter. Cora Capital Advisors LLC now owns 5,343 shares of the company’s stock valued at $423,000 after acquiring an additional 125 shares in the last quarter. Saiph Capital LLC lifted its holdings in Merck & Co., Inc. by 3.7% in the 1st quarter. Saiph Capital LLC now owns 3,565 shares of the company’s stock worth $320,000 after purchasing an additional 128 shares during the last quarter. Finally, Physician Wealth Advisors Inc. lifted its holdings in Merck & Co., Inc. by 2.9% in the 2nd quarter. Physician Wealth Advisors Inc. now owns 4,587 shares of the company’s stock worth $363,000 after purchasing an additional 128 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors.

Merck & Co., Inc. Price Performance

NYSE:MRK opened at $87.54 on Friday. The stock has a market cap of $218.65 billion, a P/E ratio of 13.49, a PEG ratio of 0.96 and a beta of 0.37. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $106.49. The company has a fifty day moving average price of $84.43 and a 200 day moving average price of $81.56. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.42 and a quick ratio of 1.17.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $2.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.03 by $0.10. Merck & Co., Inc. had a net margin of 25.79% and a return on equity of 41.05%. The company had revenue of $15.81 billion for the quarter, compared to analyst estimates of $15.92 billion. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. Analysts anticipate that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have commented on MRK. Morgan Stanley lowered their price target on Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating on the stock in a report on Thursday, July 10th. Citigroup initiated coverage on shares of Merck & Co., Inc. in a report on Monday, October 13th. They set a “neutral” rating and a $95.00 price objective for the company. Berenberg Bank lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and lowered their target price for the company from $100.00 to $90.00 in a research note on Wednesday, September 17th. Wells Fargo & Company cut their target price on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 30th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Merck & Co., Inc. in a report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $104.33.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.